Hemorrhagic Transformation (HT) and Symptomatic Intracerebral Hemorrhage (sICH) Risk Prediction Models for Postthrombolytic Hemorrhage in the Stroke Belt
- PMID: 24504047
- PMCID: PMC3912845
- DOI: 10.1155/2013/681673
Hemorrhagic Transformation (HT) and Symptomatic Intracerebral Hemorrhage (sICH) Risk Prediction Models for Postthrombolytic Hemorrhage in the Stroke Belt
Abstract
Background: Symptomatic intracerebral hemorrhage (sICH) remains the most feared complication of intravenous tissue plasminogen activator (IV tPA) treatment. We aimed to investigate how previously validated scoring methodologies would perform in treated patients in two US Stroke Belt states.
Methods and results: We retrospectively reviewed consecutive patients from two centers in two Stroke Belt states who received IV tPA (2008-2011). We assessed the ability of three models to predict sICH. sICH was defined as a type 2 parenchymal hemorrhage with deterioration in National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points or death. Among 457 IV tPA-treated patients, 19 (4.2%) had sICH (mean age 68, 26.3% Black, 63.2% female). The Cucchiara model was most predictive of sICH in the entire cohort (AUC: 0.6528) and most predictive of sICH among Blacks (OR = 6.03, 95% CI 1.07-34.1, P = 0.0422) when patients were dichotomized by score.
Conclusions: In our small sample from the racially heterogeneous US Stroke Belt, the Cucchiara model outperformed the other models at predicting sICH. While predictive models should not be used to justify nontreatment with thrombolytics, those interested in understanding contributors to sICH may choose to use the Cucchiara model until a Stroke Belt model is developed for this region.
Figures
Similar articles
-
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104360. doi: 10.1016/j.jstrokecerebrovasdis.2019.104360. Epub 2019 Sep 14. J Stroke Cerebrovasc Dis. 2019. PMID: 31501036
-
Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis.Stroke. 2013 Jun;44(6):1561-6. doi: 10.1161/STROKEAHA.111.000651. Epub 2013 Apr 30. Stroke. 2013. PMID: 23632979
-
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.Stroke. 2012 Jun;43(6):1524-31. doi: 10.1161/STROKEAHA.111.644815. Epub 2012 Mar 22. Stroke. 2012. PMID: 22442178 Clinical Trial.
-
Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.Cerebrovasc Dis. 2012;34(2):106-14. doi: 10.1159/000339675. Epub 2012 Aug 1. Cerebrovasc Dis. 2012. PMID: 22868870 Review.
-
Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2685-93. doi: 10.1016/j.jstrokecerebrovasdis.2015.07.021. Epub 2015 Nov 2. J Stroke Cerebrovasc Dis. 2015. PMID: 26542821 Review.
Cited by
-
GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.Mol Neurobiol. 2016 Dec;53(10):7028-7036. doi: 10.1007/s12035-015-9607-2. Epub 2015 Dec 15. Mol Neurobiol. 2016. PMID: 26671619 Free PMC article.
References
-
- Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases. 2008;vol. 17(no. 6):331–333. - PubMed
-
- Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;vol. 43:1524–1531. - PubMed
-
- Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke. 2007;vol. 38(no. 2):414–416. - PubMed
-
- Marler JR. Tissue plasminogen activator for acute ischemic stroke. The New England Journal of Medicine. 1995;vol. 333(no. 24):1581–1587. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources